Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. This has led drug developers to unintentionally limit their potential within chosen therapeutic spaces.

Drug Development

Drug Target Review

JULY 21, 2025

However, the advanced nature of the drugs being developed has brought new challenges. Current challenges in CNS drug development Drug development for the CNS is particularly challenging and researchers face several hurdles to producing effective and safe treatments, many of which are unique to the CNS.

Drug Development

PPD

NOVEMBER 11, 2024

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.

Drug Development

Drug Patent Watch

OCTOBER 28, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.

Pharmaceutical Companies

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International

Drug Patent Watch

JULY 15, 2025

"Breaking Down Barriers: How Mutual Recognition Agreements Can Revolutionize Generic Drug Approvals As the pharmaceutical industry continues to grapple with the complexities of global regulatory frameworks, a little-known solution is gaining traction: Mutual Recognition Agreements (MRAs).

Pharmaceutical Companies

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA

FDA Law Blog: Biosimilars

MARCH 18, 2025

Even though the PTE provisions established in the Drug Price Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension. The Court thus explained that interpreting the patent in 35 U.S.C.

Pharmaceutical Companies

Drug Target Review

JULY 31, 2025

While antibodies have long been a cornerstone of biomedical research, innovation in recombinant DNA technology over the past few decades has redefined possibilities in drug discovery and development.

Engineering

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. My experience as an optimization scientist has shown how automation can be a valuable tool to support drug development for sponsors of all sizes.

Pharmacokinetics

The Pharma Data

JUNE 18, 2025

A Next-Generation Antibody-Drug Conjugate Targeting B7-H3 Ifinatamab deruxtecan is a potential first-in-class antibody-drug conjugate (ADC) specifically engineered to target B7-H3 , a surface protein overexpressed in many solid tumors, including prostate cancer. Source link

Trials

Drug Patent Watch

AUGUST 11, 2025

"Revolutionizing the Way We Prescribe: How Data-Driven Insights Are Redefining Formulary Automation As healthcare costs continue to soar, pharmaceutical companies, payers, and providers are under increasing pressure to optimize formulary management. That's where data-driven innovation comes in.

Clinical Trials

Drug Patent Watch

JUNE 9, 2025

"Navigating the Maze of Regulations: How Pharmaceutical Companies Can Safeguard Their Drug Portfolios As the pharmaceutical industry continues to evolve, regulatory environments are becoming increasingly complex.

Pharmaceutical Companies

The Pharma Data

JUNE 13, 2025

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. The main objective of MEDISO is to aid Japanese drug-discovery ventures in navigating the complex path toward commercial readiness.

Research

Alta Sciences

JULY 3, 2025

Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.

Small Molecule

SugarCone Biotech

JUNE 27, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. ADC: Antibody-Drug Conjugates First it is important to put this wave of drug development into perspective.

Therapies

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Now to antibody-drug conjugates (ADC) where we saw some early programs with difficult toxicities. An awesome space to watch.

Therapies

Drug Patent Watch

FEBRUARY 27, 2025

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. This is a nightmare scenario for any pharmaceutical company, and it's a reality that many face every day.

Marketing

Drug Patent Watch

MAY 19, 2025

"Revolutionizing the Pharmaceutical Industry: How AI-Powered Portfolio Management is Changing the Game As the pharmaceutical landscape continues to evolve, companies are under increasing pressure to optimize their portfolios and stay ahead of the competition.

Pharmaceuticals

Drug Target Review

MARCH 4, 2025

In this interview, Bagnall explains how this approach is improving patient outcomes and driving the development of better obesity drugs. Knowing a patients subtype or phenotype can be used to guide obesity treatments of all kinds, including drug therapy, devices, bariatric surgery and even diet and lifestyle interventions, Bagnall explains.

Therapies

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. The addition of Drug Product assets for cytotoxic substances completes the fully integrated offering.

Small Molecule

The Pharma Data

JUNE 24, 2025

In just three years, nine promising research projects have received funding under the program, setting the stage for innovative breakthroughs in drug discovery. This program was specifically designed to support early-stage scientific research with high translational potential.

Pharma R&D

DrugBank

JUNE 18, 2025

Drug development is a complex and highly regulated process. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global counterparts, set rigorous standards to ensure that drugs are safe, effective, and high-quality. Regulatory agencies, such as the U.S.

Drug Development

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. “Then, the organoid model would be tested with, say, five, six, or seven drugs available on the market. .

Disease

Drug Patent Watch

FEBRUARY 13, 2025

The Unsung Heroes of Generic Drug Development: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development

Drug Target Review

JULY 14, 2025

The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues.

Drugs

Drug Target Review

JUNE 18, 2025

In early-stage drug discovery, pressure is nothing new. However, when that pressure is compounded by political shifts, market volatility and rising expectations from the global pharmaceutical industry, the old ways of working start to crack. President Trump’s proposals to reduce drug prices in the US are a key example.

Drugs

Drug Target Review

JUNE 14, 2025

I began developing my own scripts to streamline processes, which led me into scientific informatics, where I worked with pharmaceutical companies on cheminformatics. His work has contributed to innovations in computational drug discovery, antibody developability prediction and laboratory automation.

Laboratories

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. Antibiotics From the Ground Up Researchers unearthed the first TB drug from the ground. We need better vaccines — and medicines — to quash TB.

Vaccine

Drug Patent Watch

NOVEMBER 11, 2024

Effective management of drug patent portfolios is crucial for pharmaceutical companies to maintain market exclusivity, protect revenue streams, and drive innovation. A robust patent strategy aligned with business goals is essential for maximizing value and staying competitive in the pharmaceutical landscape.

Pharmaceutical Companies

Drug Patent Watch

DECEMBER 17, 2024

The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Today, they’re strategic partners in drug development and manufacturing, offering end-to-end solutions that can make or break a pharmaceutical company’s success.

Pharmaceuticals

The Pharma Data

JULY 3, 2025

NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of its first biosimilar drug, NIOPEG® , in Canada. The global market for NEULASTA® and its biosimilars is substantial.

Marketing

BioPharma Drive: Drug Pricing

JUNE 11, 2025

SciePro via Getty Images Dive Brief: The Food and Drug Administration has approved a new oral medication for an uncommon kind of tumor, clearing Nuvation Bio’s Ibtrozi on Wednesday for certain people whose metastatic non-small cell lung cancer has a type of alteration in the gene ROS1. though the drug’s commercial prospects are unclear.

FDA

ACTO

DECEMBER 17, 2024

Yet, the critical question remains: How can pharmaceutical companies ensure responsible and compliant AI implementation while maximizing its potential for field teams? Such cross-functional collaboration ensures consistent implementation from drug development through commercialization.

Government

Drug Patent Watch

APRIL 14, 2025

"Compliance in Generic Drug Development: A Critical Component of Success As the generic drug industry continues to grow, ensuring compliance with regulatory requirements has become a top priority for pharmaceutical companies.

Compliance

Drug Patent Watch

DECEMBER 8, 2024

However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies. In this article, we will delve into the strategies and considerations for handling drug patent… Source

Biosimilars

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. This is an active drug development landscape with a lot of recent news. months (see [link] ).

Drug Development